logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis Says EC Oks Signifor To Treat Adult Patients With Cushing's Disease

Novartis (NVS: Quote) said that the European Commission has approved Signifor (pasireotide) for the treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed. Signifor is the first medicine to be approved in the European Union targeting Cushing's disease, a disorder caused by excess cortisol in the body due to the presence of a non-cancerous pituitary tumor.

The decision follows the positive opinion the Committee for Medicinal Products for Human Use adopted for Signifor in January 2012 for the treatment of Cushing's disease and applies to all 27 EU member states, plus Iceland and Norway.

The company noted that the approval is based on data from the largest randomized Phase III study to evaluate a medical therapy in patients with Cushing's disease. In the study, majority of patients experienced a rapid and sustained decrease in mean cortisol levels with a subset of patients achieving normalization. Mean urinary-free cortisol (UFC) levels were normalized in 26.3% and 14.6% of the 162 patients randomized to receive Signifor 900µg and 600µg subcutaneous injection twice daily, respectively, at month six. The primary endpoint, the proportion of patients who achieved normalization of UFC after six months without dose up-titration relative to randomized dose, was met in patients treated with 900µg twice daily.

In addition, the study showed the majority of the patients remaining on the study at month six had any reduction in their mean UFC. The median reduction in mean UFC was 47.9% in both dose groups.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Courier Corp. (CRRC) announced Wednesday that its Board has reasonably determined that the non-binding, unsolicited proposal from R.R. Donnelley & Sons Company (RRD) to acquire the Company for $23.00 per share in cash or RR Donnelley common stock is reasonably likely to result in a "Superior Proposal"... Diversified electronics maker TE Connectivity Ltd. agreed Wednesday to sell its broadband network solutions or BNS business unit to telecommunications company CommScope Holding Co., Inc. in an all-cash deal valued at about $3 billion. The sale will enable TE to focus on providing leading connectivity and sensor solutions, particularly harsh environment connectivity. Online foreign exchange trading company FXCM Inc (FXCM) on Wednesday announced its decision to forgive about 90% of its clients who incurred negative balances in certain jurisdictions, on January 15 as a result of the Swiss National Bank announcement on that date. FXCM will notify the applicable clients...
comments powered by Disqus
RELATED NEWS
Trade NVS now with 
Follow RTT